Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate...

Descripción completa

Detalles Bibliográficos
Autores principales: Morschhauser, Franck, Nastoupil, Loretta, Feugier, Pierre, Schiano de Colella, Jean-Marc, Tilly, Hervé, Palomba, Maria Lia, Bachy, Emmanuel, Fruchart, Christophe, Libby, Edward N., Casasnovas, Rene-Olivier, Flinn, Ian W., Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L., Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Le Gouill, Steven, Daguindau, Nicolas, Guidez, Stéphanie, Pica, Gian Matteo, García-Sancho, Alejandro Martín, López-Guillermo, Armondo, Larouche, Jean-François, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Kalung, Wu, Sehn, Laurie H., Izutsu, Koji, Cartron, Guillaume, Gkasiamis, Argyrios, Crowe, Russell, Xerri, Luc, Fowler, Nathan H., Salles, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
CLINICAL TRIAL UPDATES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553375/
https://www.ncbi.nlm.nih.gov/pubmed/35947804
http://dx.doi.org/10.1200/JCO.22.00843

Ejemplares similares

Ejemplares similares